Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22875382 | 0.92 | L3MBTL1 (0.66) | L3MBTL1HSD11B1KDM4EPOLBALDH1A1 | |
| SCHEMBL12384614 | 0.84 | ALDH1A1 (0.62) | L3MBTL1HSD11B1KDM4EPOLBALDH1A1 | |
| SCHEMBL22549554 | 0.81 | L3MBTL1 (0.71) | L3MBTL1MAPTPKMALOX12HSD11B1 | |
| SCHEMBL24663632 | 0.80 | L3MBTL1 (0.73) | L3MBTL1MAPTPKMALOX12HSD11B1 | |
| SCHEMBL2603255 | 0.80 | FNTA (0.55) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL13629928 | 0.79 | L3MBTL1 (0.77) | L3MBTL1MAPTPKMALOX12HSD11B1 | |
| SCHEMBL7309037 | 0.79 | L3MBTL1 (1.00) | L3MBTL1MAPTPKMALOX12HSD11B1 | |
| SCHEMBL22874751 | 0.79 | SMN1; SMN2 (0.58) | L3MBTL1MAPTPKMALOX12HSD11B1 | |
| SCHEMBL2603249 | 0.79 | POLB (0.68) | L3MBTL1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL13503793 | 0.78 | POLB (0.68) | L3MBTL1HSD11B1KDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | L3MBTL1 1353/4885MAPT 2471/4885PKM 3523/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | L3MBTL1 887/4885MAPT 2456/4885PKM 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.